254 related articles for article (PubMed ID: 19039322)
1. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
2. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Levinson NM; Boxer SG
PLoS One; 2012; 7(4):e29828. PubMed ID: 22493660
[TBL] [Abstract][Full Text] [Related]
3. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia.
Kantarjian HM; Jabbour EJ; Lipton JH; Castagnetti F; Brümmendorf TH
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):285-297. PubMed ID: 38278737
[TBL] [Abstract][Full Text] [Related]
4. Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.
Pan C; Olsen JV; Daub H; Mann M
Mol Cell Proteomics; 2009 Dec; 8(12):2796-808. PubMed ID: 19651622
[TBL] [Abstract][Full Text] [Related]
5. [Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group)].
Rea D; Cayssials E; Charbonnier A; Coiteux V; Etienne G; Goldwirt L; Guerci-Bresler A; Huguet F; Legros L; Roy L; Nicolini FE
Bull Cancer; 2024 Jan; 111(1):87-96. PubMed ID: 38087729
[TBL] [Abstract][Full Text] [Related]
6. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.
Patras de Campaigno E; Bondon-Guitton E; Laurent G; Montastruc F; Montastruc JL; Lapeyre-Mestre M; Despas F
Br J Clin Pharmacol; 2017 Jul; 83(7):1544-1555. PubMed ID: 28098949
[TBL] [Abstract][Full Text] [Related]
7. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
Kim WG; Guigon CJ; Fozzatti L; Park JW; Lu C; Willingham MC; Cheng SY
Clin Cancer Res; 2012 Mar; 18(5):1281-90. PubMed ID: 22271876
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
Taylor JW; Dietrich J; Gerstner ER; Norden AD; Rinne ML; Cahill DP; Stemmer-Rachamimov A; Wen PY; Betensky RA; Giorgio DH; Snodgrass K; Randall AE; Batchelor TT; Chi AS
J Neurooncol; 2015 Feb; 121(3):557-63. PubMed ID: 25411098
[TBL] [Abstract][Full Text] [Related]
9. Bosutinib for Chronic Myeloid Leukemia.
Breccia M; Binotto G
Rare Cancers Ther; 2015; 3(1):35-46. PubMed ID: 27182477
[TBL] [Abstract][Full Text] [Related]
10. Bosutinib Stimulates Macrophage Survival, Phagocytosis, and Intracellular Killing of Bacteria.
da Silva RAG; Stocks CJ; Hu G; Kline KA; Chen J
ACS Infect Dis; 2024 May; 10(5):1725-1738. PubMed ID: 38602352
[TBL] [Abstract][Full Text] [Related]
11. Appraisal of folate functionalized bosutinib cubosomes against hepatic cancer cells: In-vitro, In-silico, and in-vivo pharmacokinetic study.
Nisha R; Kumar P; Mishra N; Maurya P; Ahmad S; Singh N; Saraf SA
Int J Pharm; 2024 Apr; 654():123975. PubMed ID: 38452833
[TBL] [Abstract][Full Text] [Related]
12. SRC: a century of science brought to the clinic.
Aleshin A; Finn RS
Neoplasia; 2010 Aug; 12(8):599-607. PubMed ID: 20689754
[TBL] [Abstract][Full Text] [Related]
13. The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.
Shkreta L; Toutant J; Delannoy A; Durantel D; Salvetti A; Ehresmann S; Sauvageau M; Delbrouck JA; Gravel-Trudeau A; Comeau C; Huard C; Coulombe-Huntington J; Tyers M; Grierson D; Boudreault PL; Chabot B
Oncotarget; 2024 May; 15():313-325. PubMed ID: 38753413
[TBL] [Abstract][Full Text] [Related]
14. Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.
Liu QS; Ass'ad NA; Arana Yi C
Clin Case Rep; 2021 May; 9(5):e03164. PubMed ID: 34094551
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of kinase inhibitor selectivity.
Davis MI; Hunt JP; Herrgard S; Ciceri P; Wodicka LM; Pallares G; Hocker M; Treiber DK; Zarrinkar PP
Nat Biotechnol; 2011 Oct; 29(11):1046-51. PubMed ID: 22037378
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Thorough QT study results using action potential simulations based on ion channel screens.
Mirams GR; Davies MR; Brough SJ; Bridgland-Taylor MH; Cui Y; Gavaghan DJ; Abi-Gerges N
J Pharmacol Toxicol Methods; 2014; 70(3):246-54. PubMed ID: 25087753
[TBL] [Abstract][Full Text] [Related]
17. Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.
Edavana VK; Dhakal IB; Williams S; Penney R; Boysen G; Yao-Borengasser A; Kadlubar S
Drug Metab Dispos; 2013 Apr; 41(4):870-7. PubMed ID: 23371966
[TBL] [Abstract][Full Text] [Related]
18. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
Speed B; Bu HZ; Pool WF; Peng GW; Wu EY; Patyna S; Bello C; Kang P
Drug Metab Dispos; 2012 Mar; 40(3):539-55. PubMed ID: 22180047
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
